(2-amino-phenylamino)-acetic acid tert-butyl ester | 1056969-01-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2-amino-phenylamino)-acetic acid tert-butyl ester
• 英文别名: Tert-butyl 2-[(2-aminophenyl)amino]acetate；tert-butyl 2-(2-aminoanilino)acetate
• CAS: 1056969-01-7
• 化学式: C₁₂H₁₈N₂O₂
• 分子量: 222.287
• InChiKey: TWKHFVSDEQCSFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-amino-phenylamino)-acetic acid tert-butyl ester 在 三氟乙酸 作用下， 以 乙腈 为溶剂， 生成 ortho-phenylenediamine-N-acetic acid
  参考文献：
  名称：

  Structure–biodistribution relation of neutral 99mTc(CO)3-complexes with tridentate N-substituted derivatives of aminoethylglycine and phenylenediamine

  摘要：

  Derivatives of ethylenediamine-N-acetic acid (EDAA = N-aminoethylglycine = AEG) and ortho-phenylenediamine-N-acetic acid (PDAA) with uncharged substituents on one or both of the amines form neutral complexes with a [Tc-99m(CO)(3)](+)-moiety. We studied the influence of different modifications at the amines (e.g., with methyl, ethyl, butyl or benzyl groups) on the behaviour of the Tc-99m(CO)(3)-complexes in vivo in mice, with special focus on blood-brain barrier (BBB) passage. The complexes have been characterised by reversed phase HPLC, log P. electrophoresis and some of them also by LC-MS. LogP values of the Tc-99m-tricarbonyl complexes varied from -0.52 (AEG) to 2.5 (N'N'-dibenzyl-EDAA). With increasing lipophilicity, more of the activity was found in liver and intestines as compared to kidneys and urine for the more polar complexes. Brain uptake was found for the Tc-99m(CO)(3)-complexes with N,N'-dibutyl-ethylenediamine-N-acetic acid (0.34% of I.D. after 2 min) and ortho-phenylenediamine-N-acetic acid (0.22% of I.D. after 2 min). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.04.136
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 邻苯二胺 在 二异丙胺 作用下， 以 甲醇 为溶剂， 生成 (2-amino-phenylamino)-acetic acid tert-butyl ester
  参考文献：
  名称：

  Structure–biodistribution relation of neutral 99mTc(CO)3-complexes with tridentate N-substituted derivatives of aminoethylglycine and phenylenediamine

  摘要：

  Derivatives of ethylenediamine-N-acetic acid (EDAA = N-aminoethylglycine = AEG) and ortho-phenylenediamine-N-acetic acid (PDAA) with uncharged substituents on one or both of the amines form neutral complexes with a [Tc-99m(CO)(3)](+)-moiety. We studied the influence of different modifications at the amines (e.g., with methyl, ethyl, butyl or benzyl groups) on the behaviour of the Tc-99m(CO)(3)-complexes in vivo in mice, with special focus on blood-brain barrier (BBB) passage. The complexes have been characterised by reversed phase HPLC, log P. electrophoresis and some of them also by LC-MS. LogP values of the Tc-99m-tricarbonyl complexes varied from -0.52 (AEG) to 2.5 (N'N'-dibenzyl-EDAA). With increasing lipophilicity, more of the activity was found in liver and intestines as compared to kidneys and urine for the more polar complexes. Brain uptake was found for the Tc-99m(CO)(3)-complexes with N,N'-dibutyl-ethylenediamine-N-acetic acid (0.34% of I.D. after 2 min) and ortho-phenylenediamine-N-acetic acid (0.22% of I.D. after 2 min). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.04.136

文献信息

• Quinoxalinones
  申请人：Beavers Pat Mary

  公开号：US20050148586A1

  公开（公告）日：2005-07-07

  The invention features quinoxalinones, pharmaceutical compositions containing them and methods of using them to treat, for example, diabetes.

  这项发明涉及喹喔啉酮，包含它们的药物组合物以及使用它们治疗糖尿病等疾病的方法。
• 酚类黄连素苯并咪唑化合物及其制备方法和应用
  申请人：西南大学

  公开号：CN111018853A

  公开（公告）日：2020-04-17

  本发明涉及酚类黄连素苯并咪唑化合物及其制备方法和应用，属于化学合成技术领域，酚类黄连素苯并咪唑化合物如通式I所示，该类化合物对革兰阳性菌、革兰阴性菌和/或真菌中的一种或多种具有一定抑制活性，可以用于制备抗细菌和/或抗真菌药物，从而有机会为临床抗微生物治疗提供更多安全、高效的多样化候选药物。其制备原料简单，廉价易得，合成路线短，在抗感染方面的应用具有重要意义。
• Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against <i>Staphylococcus aureus</i>
  作者：Hang Sun、Mohammad Fawad Ansari、Bo Fang、Cheng-He Zhou

  DOI：10.1021/acs.jafc.1c02545

  日期：2021.7.21
• (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1711184A1

  公开（公告）日：2006-10-18
• [EN] (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY<br/>[FR] DERIVES DE (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE ET COMPOSES AFFERENTS COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE DANS LE TRAITEMENT DU DIABETE ET DE L'OBESITE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005067932A1

  公开（公告）日：2005-07-28

  The invention features pharmaceutically active quinoxalinones of formula (1), compositions containing them, and methods of making and using theme: Formula (I) wherein R1 is H, C 1-6 alkyl, or halo; R2 is H or halo; R3 is H, C 1-6 alkyl, X is N or CH; Y is a covalent bond, -NHCO- or -CONH-; Z is phenyl or a 5 or 6-membered heterocyclyl with between l and 2 heteroatoms independently selected from N, O, and S; and n is 0, 1 or 2; or a pharmaceutically acceptable salt, ester, amide, hydrate, or solvate thereof; as well as their use as glycogen phosphorylase inhibitors for the treatment of i diabetes and obesity.